Providing the project management expertise to help Imperial's academics successfully lead high profile, EU funded initiatives.

The Research Project Management team provide Imperial's academics with a range of programme and project management services including:

  • Consortium management
  • Horizon 2020 proposals
  • Risk management
  • Budget and resource management
  • Co-ordination and reporting
  • Research impact
  • Exploitation, dissemination and communication
  • Liason with EC and project partners

Case studies


3D-games for TUNing and lEarnINg about hearing aids

3d TuneIn

3D Tune-In is a €3.3 million project (2015-2018) supported by the Horizon2020 ICT programme of the European Commission. Its purpose is to use Virtual Reality and 3D gaming technologies to assist hearing impaired users to gain an improved understanding of how to use their hearing aid.

The project is led by Dr Lorenzo Picinali from the Dyson School of Design Engineering at Imperial College London. 3D Tune-In brings together relevant stakeholders from academic institutions as well as traditional gaming industries, a large European hearing aid manufacturer and hearing communities to produce digital games in the field of hearing aid technologies and hearing loss in children and older adults.

At RPM we provide consortium management to the 8 partner institutions from 3 different European countries.

For more information please visit our project’s website at, follow us on twitter or have a look at our project video on youtube.

3D Tune-in news

Audiology World News

3D Tune-In at the Imperial Festival


EAVI 2020


EAVI2020 is a 23 million euro initiative to accelerate the search for an effective HIV vaccine.

The EAVI2020 consortium, which is led by Imperial College London, brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA, pooling their knowledge and expertise to develop novel candidate vaccines that can be taken through to human trials within five years. EAVI2020 is funded with an EU-grant under the health program of Horizon 2020 for research and innovation.

To keep up to date with EAVI2020, you can visit the project's website, or follow their work on Twitter.

EAVI 2020 and HIV News

HIV scientists launch 23 million euro project to develop vaccine

HIV scientists launch £17 million project to develop vaccine

Charlie Sheen and the chase for an HIV vaccine

Is the end of AIDS in sight? 10 facts about HIV/AIDS ahead of World AIDS Day

EDEN 2020

EDEN 2020 logo

Due to an aging population and the spiralling cost of brain disease in Europe and beyond, EDEN2020 aims to develop the gold standard for one-stop diagnosis and minimally invasive treatment in neurosurgery. Supported by a clear business case, it will exploit the unique track record of leading research institutions and key industrial players in the field of surgical robotics to overcome the current technological barriers that stand in the way of real clinical impact. EDEN2020 will contribute to the wider clinical challenge of extending and enhancing the quality of life of cancer patients – with the ability to plan therapies around delicate tissue structures and with unparalleled delivery accuracy.

EDEN2020 will provide a step change in the modelling, planning and delivery of diagnostic sensors and therapies to the brain via flexible surgical access, with an initial focus on cancer therapy. It will engineer a family of steerable catheters for chronic disease management that can be robotically deployed and kept in situ for extended periods. The system will feature enhanced autonomy, surgeon cooperation, targeting proficiency and fault tolerance with a suite of technologies that are commensurate to the unique challenges of neurosurgery.

The €8.6mn project, which involves 8 industrial and academic partners from the UK, Italy, the Netherlands and Germany is coordinated by Imperial College’s Prof Ferdinando Rodriguez y Baena (Faculty of Engineering, Department of Mechanical Engineering). PMO provides consortium management and leads dissemination, communication and exploitation activities.


PERFORM is an €18 million collaborative project funded under the European Commission’s Horizon 2020 programme for research and innovation.

This five-year project will look at ways to reduce antibiotic misuse, through the development of improved tests used to distinguish
bacterial from viral infections. Currently, doctors have very limited capacity to reliably differentiate life-threatening bacterial infections from trivial viral illnesses in children. As a result, thousands of children worldwide undergo investigations such as lumbar punctures, x-rays and blood cultures, and are treated with broad spectrum antibiotics while waiting to rule out bacterial infection.

PerFORMProf. Michael Levin, lead PI and Professor of International Child Health at Imperial says “better tests to identify those children with life threatening infection amongst the infinitely more numerous children with viral infections are urgently needed if antibiotic use is to be reduced. We have exciting pilot data which shows that bacterial infection can be recognised by the patterns of genes and proteins switched on in each child’s blood during infection. PERFORM will apply sophisticated genomic and proteomic methods to study thousands of febrile children with the aim of identifying and developing a better test for bacterial infection than what is currently available.”

The consortium is led by Imperial College London, with partners in Oxford, Liverpool, Spain, Austria, Germany, the Netherlands, Greece, Slovenia, Latvia and Switzerland, along with two biotechnology companies (Micropathology Ltd in the UK and bioMérieux in France). PERFORM will study over 5 000 children presented to medical care with a fever, as well as collecting data on over 50 000 children suffering with a fever who present to hospitals across the partners' countries.

The project officially started in January 2016 and it’s “Kick-Off” meeting was held in London on 11-12 January.

More information will soon be available at


PREvention of Stroke in Intracerebral hermorrhaGE survivor with Atrial Fibrillation

PRESTIGE-AF is a €7 million European Commission funded project (2017-2022) that brings together scientists and clinicians across Europe to reduce the risk of Stroke in patients.

PRESTIGE-AF addresses the unmet need of best antithrombotic stroke prevention in Intracerebral haemorrhage (ICH) patients with atrial fibrillation (AF). Recurrent stroke reduces individual life expectancy, quality of life and has high public health impact. The project’s consortium will generate new tools to tailor prevention.

The project is led by Professor Roland Veltkamp from the Department of Medicine at Imperial College London and involves 11 other partner institutions throughout the UK and across Europe including Denmark, Germany and France. The consortium members will work collaboratively within the European Commission framework to deliver the desired outcomes over 5 years.

RPM is providing the Consortium Management for the project as well as dissemination, communication and exploitation management.

To keep up to date with PRESTIGE-AF, you can visit the project's website or follow our work on Twitter.